C反应蛋白启动子区-717A/G基因多态性与C反应蛋白水平及脑梗死关系的研究
|
摘要
目的:研究C反应蛋白启动子区-717A/G基因多态性与C反应蛋白水平及脑梗死的关系。方法:选择脑梗死病例125例及正常对照组130例,测定身高、体重、收缩压、舒张压、空腹血糖、C反应蛋白、红细胞压积、血小板数、血小板体积、凝血酶原时间、凝血酶原活动度、活化部分凝血酶原时间、凝血酶时间、纤维蛋白原、甘油三脂、胆固醇、低密度脂蛋白、高密度脂蛋白等生化指标。用外周血提取DNA,采用PCR-RFLP方法确定启动子区-717A/G基因型及其多态性。利用χ~2检验对脑梗死病例组及正常对照组间基因型、等位基因频率比较。对所有个体颈动脉内膜中层厚度分组,对脑梗死病例组按梗死灶大小分组,并对脑梗死病例组按NIHSS评分分组。采用χ~2检验,分别对每种分组的不同组别进行等位基因频率比较。以比值比(OR)及95%可信区间(CI)表示各种基因型、等位基因与疾病风险的相关性,P＜0.05为差异有显著意义。应用SAS9.1.3统计软件,计算均数,标准差,百分率等,对计量资料的AA、AG、GG各基因型间的比较进行单因素方差分析,采用logistic回归分析筛选对脑梗死的主要危险因素。结果:病例组等位基因A的频率为0.84,对照组A的频率为0.79,病例组等位基因A的频率要高于对照组,但无统计学意义。对所有个体颈动脉内膜中层厚度分组,启动子区-717A/G等位基因频率与颈动脉内膜中层厚度差异无统计学意义。对脑梗死病例组按梗死灶大小分组,并对脑梗死病例组按NIHSS评分分组,启动子-717A/G等位基因频率与梗死灶大小差异有统计学意义,A等位基因在小灶梗死中的频率明显低于中灶梗死和大灶梗死;同时,启动子区-717A/G等位基因频率与NIHSS评分分组差异有统计学意义,A等位基因在轻型组中的频率明显低于重型组。我们又发现,含有从型与AG型个体的血清CRP水平明显高于GG型个体。这说明等位基因A可能有增加C反应蛋白水平的趋势。病例组胆固醇、甘油三酯、血糖、C反应蛋白、纤维蛋白原、收缩压明显高于对照组。通过逻辑回归分析,与脑梗死相关性作用由大到小分别是:C反应蛋白,胆固醇,血糖,纤维蛋白原,年龄,收缩压。结论:以上研究表明,位点-717A/G可能与脑梗死的程度和病情的严重性相关。等位基因A在发生大面积脑梗死的患者中频率较高。另外,C反应蛋白、胆固醇、血糖、纤维蛋白原、年龄、收缩压等因素对脑梗死的有直接作用。
Objective:To study the relationships between the -717A/G functional polymorphism of C-reactive protein promoter with C-reactive protein level and cerebral infarction.
Methods:In this study,125 cerebral infarction cases and 130 control cases were recruited.The following parameters were measured:height,weight,systolic blood pressure,diastolic blood pressure,fasting blood glucose,C-reactive protein, hematocrit,platelet count,platelet volume,prothrombin time,prothrombin activity,activated partial prothrombin time,thrombin time,fibrinogen, triglyceride,cholesterol,low density lipoprotein and high density lipoprotein. DNA was extracted from peripheral blood.PCR was employed afterwards for amplification.We genotyped the -717A/G locus by PCR-RFLP method.Statistical analysis was performed by Pearson's chi-square test and SPSS software was utilized for the allele and genotype association analysis.Logistic regression analysis was employed to identify the main causes of cerebral infarction.
Results:The frequency of allele A was higher in the case group than that in the control group.Statistical analysis showed that -717A/G was not associated with cerebral infarction and the inteima-media thickness for the whole samples. However,-717A was associated with the middle and big size infarction region compared with the small one.In the case group of cerebral infarction,a statistically significant difference in the distribution of the -717A allele between mild and severe patients according to NIHSS scores was also observed.In addition,the average level of C-reactive protein was higher in the AA and AG genotypic subjects than that in the GG genotypic subjects.The levels of Cholesterol,Triglycerides,Blood glucose,C-reactive protein,Fibrinogen,Systolic blood pressure were much higher in the patient group than it in the control group.By using logistic regression analysis,researchers also identified the following cerebral infarction inducing factors,which were ranked by the degree of correlation:C-reactive protein, Cholesterol,Blood glucose,Fibrinogen,Age and Systolic blood pressure.
Conclusions:There is significant relationship between the-717A/G functional polymorphism of C-reactive protein promoter with C-reactive protein level and the cerebral infarction,and -717A allele may be associated with severe cerebral infarction.C-reactive protein,Cholesterol,Fibrinogen,Blood glucose,Age and Systolic blood pressure are all risk factors of the cerebral infarction disease.
Objective:To study the relationships between the -717A/G functional polymorphism of C-reactive protein promoter with C-reactive protein level and cerebral infarction.
Methods:In this study,125 cerebral infarction cases and 130 control cases were recruited.The following parameters were measured:height,weight,systolic blood pressure,diastolic blood pressure,fasting blood glucose,C-reactive protein, hematocrit,platelet count,platelet volume,prothrombin time,prothrombin activity,activated partial prothrombin time,thrombin time,fibrinogen, triglyceride,cholesterol,low density lipoprotein and high density lipoprotein. DNA was extracted from peripheral blood.PCR was employed afterwards for amplification.We genotyped the -717A/G locus by PCR-RFLP method.Statistical analysis was performed by Pearson's chi-square test and SPSS software was utilized for the allele and genotype association analysis.Logistic regression analysis was employed to identify the main causes of cerebral infarction.
Results:The frequency of allele A was higher in the case group than that in the control group.Statistical analysis showed that -717A/G was not associated with cerebral infarction and the inteima-media thickness for the whole samples. However,-717A was associated with the middle and big size infarction region compared with the small one.In the case group of cerebral infarction,a statistically significant difference in the distribution of the -717A allele between mild and severe patients according to NIHSS scores was also observed.In addition,the average level of C-reactive protein was higher in the AA and AG genotypic subjects than that in the GG genotypic subjects.The levels of Cholesterol,Triglycerides,Blood glucose,C-reactive protein,Fibrinogen,Systolic blood pressure were much higher in the patient group than it in the control group.By using logistic regression analysis,researchers also identified the following cerebral infarction inducing factors,which were ranked by the degree of correlation:C-reactive protein, Cholesterol,Blood glucose,Fibrinogen,Age and Systolic blood pressure.
Conclusions:There is significant relationship between the-717A/G functional polymorphism of C-reactive protein promoter with C-reactive protein level and the cerebral infarction,and -717A allele may be associated with severe cerebral infarction.C-reactive protein,Cholesterol,Fibrinogen,Blood glucose,Age and Systolic blood pressure are all risk factors of the cerebral infarction disease.
引文
[1] Taubes G(2002)Does inflammation cut to the heart of the matter? Science 296:242-245.
[2] Ross R(1999)Atherosclerosis:an inflammatory disease.N Engl J Med 340:115-126.
[3] Libby P(1995)Molecular bases of the acute coronary syndromes.Circulation 91:2844-2850.
[4] Libby P,Ridker PM(1999)Novel inflammatory markers of coronary risk:theory versus practice.Circulation 100:1148-1150.
[5] Rader DJ(2000)Inflammatory markers of coronary risk.N Engl J Med 343:1179-1182.
[6] Lindahl B,Toss H,Siegbahn A,Venge P,Wallentin L(2000)Markers of myocardial damage and inflammation in relation tolong-term mortality in unstable coronary disease.N Engl J Med 343:1139-1147.
[7] Liuzzo G,Biasucci LM,Gallimore JR,Grillo RL,Rebuzzi AG,Pepys MB,Maseri A(1994)The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.N Engl J Med 331:417-424.
[8] Biasucci LM,Liuzzo G,Grillo RL,Caligiuri G,Rebuzzi AG,Buffon A,Summaria F,Ginnetti F,Fadda G,Maseri A(1999)Elevated levels of C-reactive protein at discharge in atientswith unstable angina predict recurrent instability.Circulation99:855-860.
[9] Ferreiros ER,Boissonnet CP,Pizarro R,Merletti PF,Corrado G,Cagide A,Bazzino OO(1999)Independent prognostic value of elevated C-reactive protein in unstable angina.Circulation100:1958-1963.
[10] Hak AE,Stehouwer CD,Bots ML,Polderman KH,SchalkwijkCG,Westendorp IC,Hofman A,Witteman JC(1999)Association of C-reactive protein with measures of obesity,insulin resistance,and subclinical atherosclerosis in healthy,middleaged women.Arterioscler Thromb Vasc Biol 19:1986-1991.
[11]Visser M,Bouter LM,Mcquitlan GM,Wener MH,Harris TB(1999) Elevated C-reactive protein levels in overweight and obese adults.JAMA 282:2131-2135.
[12]Yudkin JS,Stehouwer CD,Emeis JJ,Coppack SW(1999) Creactive protein in healthy subjects:associations with obesity,insulin resistance,and endothelial dysfunction:a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
[13]Du Clos TW(2000) Function of C-reactive protein.Ann Med 32:274-278.
[14]Klein TC,Doffinger R,Pepys MB,Ruther U,Kyewski B(1995) Tolerance and immunity to the inducible self-antigen Creactive protein in transgenic mice.Eur J Immunol 25:3489-3495.
[15]1995年全国第四次脑血管病学术会议,脑卒中患者临床神经功能缺损程度评分标准中附件一、附件二、附件四.中华神经科杂志,1996,29(6):383
[16]Chen J,Zhao J,Huang J,Su S,Qiang B,Gu D.-717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese:the Beijing Atherosclerosis Study.J Mol Med 2005;83:72-8.
[17]Lopez AD,Mathers CD,Ezzati M,Jamison DT,Murray CJ:Global and regional burden of disease and risk factors,2001:Systematic analysis of population health data.Lancet 2006;367:1747-1757.
[18]Brainin M,Bornstein N,Boysen G,Demarin V:Acute neurological stroke care in europe:Results of the european stroke care inventory.Eur J Neurol 2000;7:5-10.
[19]Rothwell PM,Coull AJ,Silver LE,Fairhead JF,Giles MF,Lovelock CE,Redgrave JN,Bull LM,Welch SJ,Cuthbertson FC,Binney LE,Gutnikov SA,Anslow P,Banning AP,Mant D,Mehta Z:Population-based study of event-rate,incidence,case fatality,and mortality for all acute vascular events in all arterial territories(oxford vascular study ) Lancet 2005; 366:1773-1783.
[20] O'Brien JT,Erkinjuntti T,ReisbergB,Roman G,SawadaT,Pantoni L,Bowler JV,Ballard C,DeCarli C,GorelickPB,RockwoodK,Burns A,Gauthier S,DeKosky ST:Vascular cognitive impairment.Lancet Neurol 2003;2:89-98.
[21] Gussekloo J,SchaapMC,FrolichM,et al.C-reactive protein is a strong butnonspecific risk factor of fatal stroke in elderly persons.ArteriosclerThromb Vase Bio,1 2000,20:1047-1051.
[22] Chlumskyl,CharvatJ.E ndothelialdy sfunction,di stensibility and intima-media thickness and aetiologyo fstroke.hi tM edR es,2005,33(5):555-6.
[23] NikicP,S avicM,Ja kovljevicV Intima-mediat hicknesso fc ommonc arotida rtery,carotid atherosclerosis and subtypes of ischemic cerebral disease.Rom J Intern Med,2004,42(1):149-60.
[24] HommaS,H iroseN,Is hidaH,et al.C arotidp laquean din tima-mediath icknessas sessed by B-mode ultrasono-graphy in subjects ranging from young adults to centenary-ians[J].Srtoke,2001.32(4):8 30-835.
[25] Lowe GD.The relationship between infection and cardiovascular disease[J].Ann Perio do ntol,2001;6:l-8.
[26] ChamhlessL E.Carotid wall thickness is predictive of incident clinical stroke;theArteriosclersis Risk in Communities Study[J].Am J Epidenmiol,2000:15(5):478-483.
[27] Di Napoli M.C-reactive protein in ischemic stoke:an independent prognostic factor[J].Stoke,2001;32:917-924.
[28] Hashimoto H Kitagawa K Hougaku H et al.C-reactive protein is a independent predictor of the rate of increase in earlycarotid atherosclerosis.Circulation 2001 104:63-67.
[29] Buraczynska M,Dzida G,Puzniak A,et al.Restriction fragment length polymorphisms in the apolipoprotein B gene in survivors of myocardial infarction.Med Sci Monit,2000,6(5):882-886.
[30] Verduci E,Agostoni C,Biondi ML,et al.Apolipoprotein B gene polimorphism and plasma lipid levels in phenylketonuric children.Prosta glandins,Leukot Essent Fatty Acids,2004,71(2):117-120.
[31] Venugopal SK,Devaraj S,Jialal I.C-reactive protein decrease sprostacyclin release from human aortic endothelial cells.Circulation,2003,108(14):1676-1678.
[1] ....2000.466.
[2] NaghaviM,MadjidM,Khan MR,etal.Newdovelo Pmentsin the detection of vulne rable Plaque.Cur AtherosclerRPe,2001;3(2):125-135.
[3] PasceriV,WillersonJT,etal.Direct Proin flammatory effect of C-reactive Proteinon human end otheialcells.Circulation,2000;102:2165-2168.
[4] GuvenACetinkayaA,AralM,etal.High-sensitivity C-reactiveProteinin Patienis with metab olicsyndrome.Angiology.2006May-Jnu;57(3):295-302.
[5] BhakdiS,TOrzew skiM,KloucheM,etal Com Plement and anther osclerosis:bindingof CRP to degraded,non-oxidiezd LDLehnancescom Plement activation.AtherosclerThlom bVascBiol,1999,19:2348-2354.
[6] HolvenKB,AukrustP,ReterslOK,et al.Increased levelsof C-reactive protein and inteireuik n-6 in hyPehtomocy steienmic sbjuects.Scand J Clin Lab lnvest.2006;66(l):45-54
[7] YudkinJS,StehouwerCD,EmerisJJ,et al..C-reactive Protein in healthy subjectts:association with obesity,insulin resistence,and ndothelialdy sfunction.APotential role for ctyokine oirginating form adiPose tissue?Atheroscler Tbromb Vase Biol,1999;19:972-978.
[8] VermaS,WangCH,WeiselRD,et al.Hyperglycemia potentiates the proatherogenicEffects of C-reactive protein with rosiglitozeno J Mol Cell Cardiol,2003;35:417-419.
[9] Jabs WJ,Logering BA,Gerke P,et al.The kidney as a second site of human C-reactive protein formation in vivo.Eur J Immunol 2003:33(1):152-61.
[10] Pankow JS,Folsom AR,CushmanM,et a.l Familial and genetic determinants ofsystem icmarkers of inflammation:The Nhlbifamily heart study[J]A therosclersis,2001,154:681-689.
[11] Zee RY,Ridker PM.Polymorphism in the human C-reactive protein(CRP)gene,plasma concentrations of CRP,and the risk of future arterial thrombosis[J].Atherosclerosis,2002,162:217-219.
[12] Kozan 0,Buyukozturk K,Ilerigelen B,et al.The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients:results of theICEBERG study.J Clin Hypertens,2007,9:500-505.
[13]Youssef MY,Mojiminiyi OA,Abdella NA.Plasma concentrations of C-reactive protein and total homocysteine in relationto the severity and risk factors for cerebrovascular disease.Transl Res,2007,150:158-163.
[14]Fujita M,Ueki S,Ito W,et al.C-reactive protein levels in theserum of asthmatic patients.Ann Allergy Asthma Immunol,2007,99:48-53.
[15]Peled N,Kassirer M,Shitrit D,et al.The association of OSAwith insulin resistance,inflammation and metabolic syndrome.Respir Med,2007,101:1696-1701.
[16]SchwedlerSB,AmannK,WemickeK,et a.l Native C-reactive protein increases where asmodified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockoutmice[J].Circulation,2005,112:1016-1023.
[17]Jialal I,DevarajS,VenugopalSK.C-reactive protein:Risk marker or mediator in atherothrombosis? Hypertension,2004,44(1):1-6.
[18]TaylorKE,Giddings JC,van den Berg CW.C-reactive protein-induced in vitro endothelial cell activation is an artefactcaused by azide and lipopolysaccharide[J].ArteriosclerThromb Vasc Bio,l 2005,25:1225-1230.
[19]van den BergCW,TaylorKE,LangD.C-reactive protein-induced in vitro vaso relaxation is an artefact caused by the presence of sodium azide in commercial preparations[J].Arterioscler ThrombVasc Bio,l 2004,24:e168-e171.
[20]DanenbergHD,SzalaiAJ,Swaminathan RV,et a.l Increased thrombosis afterarterial injury in human C-reactive protein-transgenic mice[J].Circulation,2003,108:512-515.
[21]PaulA,Ko KW,Li L,et a.l C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficientmice[J].Circulation,2004,109:647-655.
[22]TrionA,deMaatMP,Jukema JW,eta.l No effectofC-reactive protein on earlyatherosclerosis development in apolipoprotein E~* 3-leiden/human C-reactive protein transgenic mice[J].Arterioscler Thromb Vasc Bio,l 2005,25:1635-1640.
[23]ReifenbergK,LehrHA,BaskalD,et a.l Role of C-reactive protein in athero-genesis:can the apolipoprotein E knockoutmouse provide the answer[J]? ArteriosclerThrombVasc Bio,l 2005,25:1641-1646.
[24]HirschfieldGM,Gallimore JR,KahanMC,et a.l Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficientmice[J].Proc NatlAcad SciUSA,2005,102:8309-8314.
[25]孔令文.血清C反应蛋白检测与冠心病的关系[J]·中华全科医师杂志,2004.3:384.
[26]Pearson TA,Mensah GA,Alexander RM,et a.l Markers of inflammation and cardiovascular disease:Application to clinical and public health practice:A statement forhealthcare professionals from the Centers forDisease Control and Prevention and the American HeartAssociation[J].Circulation,2003,107:499-511.
[27]Ridker PM,Hennekens CH,Buring JE,et al.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.N Engl J Med,2000,342(12):836-843.
[28]Ayash RS.High-sensitivity C-reactive protein:productclaims and the Food and Drug Administration.Clin Chem,2001,47(9):1743.
[29]Ridker PM.High-sensitivity C-reactive protein:potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.Circulation,2001,103(13):1813-1818.
[30]Kimberly MM,Vesper HW,Caudill SP,et al.Standardization of immunoassays for measurement of high-sensitivity C-reactive protein.Phase Ⅰ:evaluation of secondary reference materials.Clin Chem,2003,49(4):611-616.
[31]CAO H,ROBERTA,HEGELE J,et al.J Hum Genet,2000,45(2):100-101.
[32]EKLUND C T,LEHTIMAKIT M,HURME I,et al.Inter J Immun,2005,32(4):229-232.
[33]SUKH J,RIDER PM,COOK N R,et al.Atherosclerosis,2005,178(1):139-145.
[34]MILLER DT,ZEERY,SUKDANIKJ,et al.AnnHumGenet,2005,69(6):623-638.
[35]CHEN JH,ZHAOJG,HUANG JF,et al.JMolMed,2005,83(1):72-78.
[36]KOVACSA,GREENF,HANSSONL O.Atherosclerosis,2005,178(1):193-198.
[37]赵磊,周新,郑芳,等.中国老年学杂志,2005,25(6):637-639.
[38]徐耕,金国栋,傅国胜,等.中华心血管病杂志,2003,31(4):274-277.
[39]尚小明,赵宝春,戴秀华,等.国外医学内科学分册,2005,32(6):269-273.
[40]VermaS,KuliszewskiMA,Li SH,et al.C-reactive protein attenuates ndothelial progenitor cell survival,diferentiation,and function:further evidence of a mechanistic link between C-reactive protein and cardiovascular disease[J].Circulation,2004;109(17):2058-2067.
[41]BassukS S,RifaiN,RidkerPM.High-sensitivity C-reactive protein:clinical importance[J].Curr Probl Cardiol.2004;29(8):439-493.
[42]BlaschkeF,BruemmerD,YinF,etal.C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells[J].Circulation,2004;110(5):579-587.
[43]DanenbergHD,SzalaiAJ,SwaminathanRV et al.Increased thrombosis after arterial injuryin human C-reactive protein-transgenic mice[J].Circulation,2003;108(5):512-515.
[44]VolanakisJ E.Human C -reactive protein:expression,structure,and function[J].MolImmunol.2001;38(2-3):189-197.
[45]Zee RY,RidkerPM.Polymorphism in the human C-reactive protein(CRP)gene,plasma concentrations of CRP,and the risk of future arterial thrombosis[J].Atherosclerosis,2002;162(1):217-219.
[46]Tohgi H,Takahashi H,Tamura K,et al.Ischemic stroke among inpatents with preceding inflame matory response[J].Thromb Res,2001,104(5):375.
[47]史功,刘玉兰,肖国民.急性脑血管病早期血清C-反应蛋白的测定及意义[J].临床荟萃,1997,12(2):87.
[48]武湘云,李立新,李贵霞.脑血管疾病与血清C-反应蛋白关系的探讨[J].临床荟萃,2004,19(13):751.
[49]高建国,周农,翟金霞.血清C反应蛋白与脑梗死预后的关系[J].临床神经病学杂志,2005,18(1):43-44.
[50]Pepys MB,Hirschfield GM.C-reactive protein:a critical up-date[J].Clin Invest,2003,111:1805-1812.
[51]Nakanishi N,Shiraishi T,Wada M.Association between C-reactive protein and insulin resistance in a Japanese population:the Minoh Study.Intern Med,2005,44(6):542-547.
[52]Howard VJ,Sides EG,Newman GC,et al.Changes in plasma homocysteine in the acute phase after stroke[J].Stroke,2002,33:473-478.
[53]Harry Yu,Nader Rifai.High-sensitivity C-reactive protein and ather sclerosis:from theory to the reply[J].Clinical Biochemistry,2000,33(8):601-601.
[54]张微微,周小英.不同类型脑梗死患者血清C-反应蛋白的检测及临床意义[J].中华检验医学杂志,2004,27:781-783.
[55]RostNS,WolfPA,KaseCS,eta.l Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack:the Framingham study.Stroke,2001,32:2575-2579.
[56]Cao JJ,Thach C,ManolioTA,eta.l C-reactive protein,carotid in tima-media thickness and incidence of ischemic stroke in the elderly:the CardiovascularHealth Study.Circulation,2003,108:166 - 170.
[57]Gussekloo J,SchaapMC,FrolichM,et a.l C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons.Arterioscler Thromb Vasc Bio,l 2000,20:1047-1051.
[58]Di NapoliM,Papa F,Bocola V.C-reactive protein in ischemic stroke:an independentprognostic factor.Stroke,2001,32:917-924.
[59] BALISTRERI C R,VASTO S,LISTI F,et al.Ann N Y Acad Sci,2006,1067(6):276-281.
[60] MORITA A,NAKAYAMA T,SOMA M,et al.Hypertens,2006,19(6):593-600.
[61] ZEE R Y,HEGENERHH,FERNANDEZ C A,et al.Atherosclerosis,2004,176(2):393-396.
[62] HIRSCHFIELD GM,GALLIMORE J,KAHANMC,et al.Natl Acad Sci,2005,102(23):8309-8314.
[63] DOI Y,KIYOHARA Y,KUBO M,et al.Diabetes Care,2005,28(10):2497-2500.
[64] MARIOMD,POMILIOM,VIGNERI S,et al.Diabetes Care,2001,24(9):1674-1678.
[65] Wolford CS,ALDRED SF,LEE PK,et al.Am J Hum Genet2005,77(1):64-74.
[66] SZALAI A J,CRORYMM,COOPER C,et al.Genes and Immunity,2002,3(1):14-19.
[67] RUSSELL A I,CUNNINGHAME G,DEBORAHS,et al.OxfordUni-versity Press,2004,13(1):137-147.
[68] THALMAIERD,DAMBACHER J,SEIDERER J,et al.AlimentPhar-macol Ther,2006,24(7):115-117.
[69] WILLOT S,VERMEIRE S,OHRESSER M,et al.Pharmacogenet Genomics,2006,16(1):37-42.
[70] EBERSOLE J L,MACHEN R L,STEFFENM J,et al.J Clinical &Experimental Immunology,1997,107(2):347-352.]
[71] MIRANDALA,FISCHER RG,SZTAJNBOKFR,et al.J Clin Periodontal,2003,30(11):969-974.
[72] D'AIUTO F,READY D,TONETTI M S,et al.J Periodont Res,2004,39(4):236-241.
[73]SLADE G D,OFFENBACHER S,BECK J D,J Dent Res,2000,79(1):49-57.
[74]MARSIK C,SUNDER P R,JILMA B,et al.Clin Chem,2006,52(10):1952-1957.
[75]Tataru M C,Heinrich J,Junker R,et al.C-reactive protein and the severity of otherosclerosis in myocardial infarction patiens with stable angina pectoris[J].Eur Heart J,2002,21(12 ):1000.
[76]徐光燕,邓志宽.阿司匹林对脑梗死患者血清C反应蛋白含量的影响及意义[J].中国临床康复,2003,7(28):3814-3815.
[77]Chen YG,Xu F,Zhang Y,et al.Effect of aspirin plus clopi-dogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.Chin Med J(Engl)2006,119:32-36.
[78]Solheim S,AmesenH,EikvarL,et a.l Influence of aspirin on inflammatory markers in patients after acutemyocardial infarction.Am JCardioj 2003,92:843-845.
[79]Ikonomids I,AndreottiF,Economon E,eta.l Increased proinflam-matory cytokines in patientswith chronic stable angina and their reduction by aspirin.Circulation,1999,100:793-798.
[80]A zar RR,Klayme S,GermanosM,et al Effects of aspirin(325mg/day) on serum high-sensitivity C-reactive protein,cytokines,and adhesionmolecules in healthy volunteers.Am JCardioj 2003,92:236-239.
[81]Ridker PM;Cushman M;Stampfer MJ et al.Inflammation,Aspirin,and the Risk of C ardiovascularD iseasein Apparently Healthy Men N.Engl.J.Med.1997;336:973-979.
[82]KennonS,PriceCP,MillsGP et al.The efect of aspirin on C -reactivep rotein as a marker of risk inunstable angina.J Am Coll Cardiol2001;37:1226-70
[83]LangloisM,DuprezD,DelangheJ et al.Serum VitamionC concentrationis low inperiph eralart erial disease and is associated within flammation and ather osclerosis.Circulation2001:1863-8.
[84]曾红,孙长凯,赵杰,等.他汀类药物对脑梗死患者血清C反应蛋白的影响
及其临床意义[J].中华神经科杂志,2005,38(5):329-330.
[85]Luo Y,Jiang D,Wen D,et al.Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin.Heart Vessels,2004,19:257-262.
[86]Ansell BJ,Watson KE,Weiss RE,et al.hsCRP and HDL effects of statins trial (CHEST):rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels.A clinical investigation.Heart Dis,2003,5:2-7.
[87]Hoshida S,Nishino M,Takeda T,et al.A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins.Atheroscle-rosis,2004,173:285-290.
[88]YudkinJ S,StehhouwerC DA,EmeisJ J etal.C-eractive protein in healthy subject:association with obesity,insulin resistance,and endothelial dysfunction.Arterioscler Thromb VaseBiol 1999;19:972-8.
[89]Hans C.Ablij,Arend E.Meinders C-reactive protein:history and revival.European J.of intenral Med2002;13:4 12-22.
[90]Chan DC;Wats GF;Barret PH et al.Efect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuas withvisceral obesity.Clin Chem.2002Jun;48(6):877-883.
[91]董玉秋.青霉素对急性脑梗死患者血清CRP的影响及疗效观察[J].山东医药2005,45(22):31.
[92]DiNapoliM,Papa F.Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration ofC-reactive protein in patientswith first-ever ischemic stroke.Stroke,2003,34:2922-2929.
[93]Jenkins NP,Keevil BG,Hutchinson Ⅳ,et al.Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.Am J Med,2002,112:269-274.
[94]Pepys MB,Hirschfield GM,Tennent GA,et al.Targeting C-reactive protein for the treatment of cardiovascular disease.Nature,2006,440:1217-1221.
[2] Ross R(1999)Atherosclerosis:an inflammatory disease.N Engl J Med 340:115-126.
[3] Libby P(1995)Molecular bases of the acute coronary syndromes.Circulation 91:2844-2850.
[4] Libby P,Ridker PM(1999)Novel inflammatory markers of coronary risk:theory versus practice.Circulation 100:1148-1150.
[5] Rader DJ(2000)Inflammatory markers of coronary risk.N Engl J Med 343:1179-1182.
[6] Lindahl B,Toss H,Siegbahn A,Venge P,Wallentin L(2000)Markers of myocardial damage and inflammation in relation tolong-term mortality in unstable coronary disease.N Engl J Med 343:1139-1147.
[7] Liuzzo G,Biasucci LM,Gallimore JR,Grillo RL,Rebuzzi AG,Pepys MB,Maseri A(1994)The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.N Engl J Med 331:417-424.
[8] Biasucci LM,Liuzzo G,Grillo RL,Caligiuri G,Rebuzzi AG,Buffon A,Summaria F,Ginnetti F,Fadda G,Maseri A(1999)Elevated levels of C-reactive protein at discharge in atientswith unstable angina predict recurrent instability.Circulation99:855-860.
[9] Ferreiros ER,Boissonnet CP,Pizarro R,Merletti PF,Corrado G,Cagide A,Bazzino OO(1999)Independent prognostic value of elevated C-reactive protein in unstable angina.Circulation100:1958-1963.
[10] Hak AE,Stehouwer CD,Bots ML,Polderman KH,SchalkwijkCG,Westendorp IC,Hofman A,Witteman JC(1999)Association of C-reactive protein with measures of obesity,insulin resistance,and subclinical atherosclerosis in healthy,middleaged women.Arterioscler Thromb Vasc Biol 19:1986-1991.
[11]Visser M,Bouter LM,Mcquitlan GM,Wener MH,Harris TB(1999) Elevated C-reactive protein levels in overweight and obese adults.JAMA 282:2131-2135.
[12]Yudkin JS,Stehouwer CD,Emeis JJ,Coppack SW(1999) Creactive protein in healthy subjects:associations with obesity,insulin resistance,and endothelial dysfunction:a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
[13]Du Clos TW(2000) Function of C-reactive protein.Ann Med 32:274-278.
[14]Klein TC,Doffinger R,Pepys MB,Ruther U,Kyewski B(1995) Tolerance and immunity to the inducible self-antigen Creactive protein in transgenic mice.Eur J Immunol 25:3489-3495.
[15]1995年全国第四次脑血管病学术会议,脑卒中患者临床神经功能缺损程度评分标准中附件一、附件二、附件四.中华神经科杂志,1996,29(6):383
[16]Chen J,Zhao J,Huang J,Su S,Qiang B,Gu D.-717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese:the Beijing Atherosclerosis Study.J Mol Med 2005;83:72-8.
[17]Lopez AD,Mathers CD,Ezzati M,Jamison DT,Murray CJ:Global and regional burden of disease and risk factors,2001:Systematic analysis of population health data.Lancet 2006;367:1747-1757.
[18]Brainin M,Bornstein N,Boysen G,Demarin V:Acute neurological stroke care in europe:Results of the european stroke care inventory.Eur J Neurol 2000;7:5-10.
[19]Rothwell PM,Coull AJ,Silver LE,Fairhead JF,Giles MF,Lovelock CE,Redgrave JN,Bull LM,Welch SJ,Cuthbertson FC,Binney LE,Gutnikov SA,Anslow P,Banning AP,Mant D,Mehta Z:Population-based study of event-rate,incidence,case fatality,and mortality for all acute vascular events in all arterial territories(oxford vascular study ) Lancet 2005; 366:1773-1783.
[20] O'Brien JT,Erkinjuntti T,ReisbergB,Roman G,SawadaT,Pantoni L,Bowler JV,Ballard C,DeCarli C,GorelickPB,RockwoodK,Burns A,Gauthier S,DeKosky ST:Vascular cognitive impairment.Lancet Neurol 2003;2:89-98.
[21] Gussekloo J,SchaapMC,FrolichM,et al.C-reactive protein is a strong butnonspecific risk factor of fatal stroke in elderly persons.ArteriosclerThromb Vase Bio,1 2000,20:1047-1051.
[22] Chlumskyl,CharvatJ.E ndothelialdy sfunction,di stensibility and intima-media thickness and aetiologyo fstroke.hi tM edR es,2005,33(5):555-6.
[23] NikicP,S avicM,Ja kovljevicV Intima-mediat hicknesso fc ommonc arotida rtery,carotid atherosclerosis and subtypes of ischemic cerebral disease.Rom J Intern Med,2004,42(1):149-60.
[24] HommaS,H iroseN,Is hidaH,et al.C arotidp laquean din tima-mediath icknessas sessed by B-mode ultrasono-graphy in subjects ranging from young adults to centenary-ians[J].Srtoke,2001.32(4):8 30-835.
[25] Lowe GD.The relationship between infection and cardiovascular disease[J].Ann Perio do ntol,2001;6:l-8.
[26] ChamhlessL E.Carotid wall thickness is predictive of incident clinical stroke;theArteriosclersis Risk in Communities Study[J].Am J Epidenmiol,2000:15(5):478-483.
[27] Di Napoli M.C-reactive protein in ischemic stoke:an independent prognostic factor[J].Stoke,2001;32:917-924.
[28] Hashimoto H Kitagawa K Hougaku H et al.C-reactive protein is a independent predictor of the rate of increase in earlycarotid atherosclerosis.Circulation 2001 104:63-67.
[29] Buraczynska M,Dzida G,Puzniak A,et al.Restriction fragment length polymorphisms in the apolipoprotein B gene in survivors of myocardial infarction.Med Sci Monit,2000,6(5):882-886.
[30] Verduci E,Agostoni C,Biondi ML,et al.Apolipoprotein B gene polimorphism and plasma lipid levels in phenylketonuric children.Prosta glandins,Leukot Essent Fatty Acids,2004,71(2):117-120.
[31] Venugopal SK,Devaraj S,Jialal I.C-reactive protein decrease sprostacyclin release from human aortic endothelial cells.Circulation,2003,108(14):1676-1678.
[1] ....2000.466.
[2] NaghaviM,MadjidM,Khan MR,etal.Newdovelo Pmentsin the detection of vulne rable Plaque.Cur AtherosclerRPe,2001;3(2):125-135.
[3] PasceriV,WillersonJT,etal.Direct Proin flammatory effect of C-reactive Proteinon human end otheialcells.Circulation,2000;102:2165-2168.
[4] GuvenACetinkayaA,AralM,etal.High-sensitivity C-reactiveProteinin Patienis with metab olicsyndrome.Angiology.2006May-Jnu;57(3):295-302.
[5] BhakdiS,TOrzew skiM,KloucheM,etal Com Plement and anther osclerosis:bindingof CRP to degraded,non-oxidiezd LDLehnancescom Plement activation.AtherosclerThlom bVascBiol,1999,19:2348-2354.
[6] HolvenKB,AukrustP,ReterslOK,et al.Increased levelsof C-reactive protein and inteireuik n-6 in hyPehtomocy steienmic sbjuects.Scand J Clin Lab lnvest.2006;66(l):45-54
[7] YudkinJS,StehouwerCD,EmerisJJ,et al..C-reactive Protein in healthy subjectts:association with obesity,insulin resistence,and ndothelialdy sfunction.APotential role for ctyokine oirginating form adiPose tissue?Atheroscler Tbromb Vase Biol,1999;19:972-978.
[8] VermaS,WangCH,WeiselRD,et al.Hyperglycemia potentiates the proatherogenicEffects of C-reactive protein with rosiglitozeno J Mol Cell Cardiol,2003;35:417-419.
[9] Jabs WJ,Logering BA,Gerke P,et al.The kidney as a second site of human C-reactive protein formation in vivo.Eur J Immunol 2003:33(1):152-61.
[10] Pankow JS,Folsom AR,CushmanM,et a.l Familial and genetic determinants ofsystem icmarkers of inflammation:The Nhlbifamily heart study[J]A therosclersis,2001,154:681-689.
[11] Zee RY,Ridker PM.Polymorphism in the human C-reactive protein(CRP)gene,plasma concentrations of CRP,and the risk of future arterial thrombosis[J].Atherosclerosis,2002,162:217-219.
[12] Kozan 0,Buyukozturk K,Ilerigelen B,et al.The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients:results of theICEBERG study.J Clin Hypertens,2007,9:500-505.
[13]Youssef MY,Mojiminiyi OA,Abdella NA.Plasma concentrations of C-reactive protein and total homocysteine in relationto the severity and risk factors for cerebrovascular disease.Transl Res,2007,150:158-163.
[14]Fujita M,Ueki S,Ito W,et al.C-reactive protein levels in theserum of asthmatic patients.Ann Allergy Asthma Immunol,2007,99:48-53.
[15]Peled N,Kassirer M,Shitrit D,et al.The association of OSAwith insulin resistance,inflammation and metabolic syndrome.Respir Med,2007,101:1696-1701.
[16]SchwedlerSB,AmannK,WemickeK,et a.l Native C-reactive protein increases where asmodified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockoutmice[J].Circulation,2005,112:1016-1023.
[17]Jialal I,DevarajS,VenugopalSK.C-reactive protein:Risk marker or mediator in atherothrombosis? Hypertension,2004,44(1):1-6.
[18]TaylorKE,Giddings JC,van den Berg CW.C-reactive protein-induced in vitro endothelial cell activation is an artefactcaused by azide and lipopolysaccharide[J].ArteriosclerThromb Vasc Bio,l 2005,25:1225-1230.
[19]van den BergCW,TaylorKE,LangD.C-reactive protein-induced in vitro vaso relaxation is an artefact caused by the presence of sodium azide in commercial preparations[J].Arterioscler ThrombVasc Bio,l 2004,24:e168-e171.
[20]DanenbergHD,SzalaiAJ,Swaminathan RV,et a.l Increased thrombosis afterarterial injury in human C-reactive protein-transgenic mice[J].Circulation,2003,108:512-515.
[21]PaulA,Ko KW,Li L,et a.l C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficientmice[J].Circulation,2004,109:647-655.
[22]TrionA,deMaatMP,Jukema JW,eta.l No effectofC-reactive protein on earlyatherosclerosis development in apolipoprotein E~* 3-leiden/human C-reactive protein transgenic mice[J].Arterioscler Thromb Vasc Bio,l 2005,25:1635-1640.
[23]ReifenbergK,LehrHA,BaskalD,et a.l Role of C-reactive protein in athero-genesis:can the apolipoprotein E knockoutmouse provide the answer[J]? ArteriosclerThrombVasc Bio,l 2005,25:1641-1646.
[24]HirschfieldGM,Gallimore JR,KahanMC,et a.l Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficientmice[J].Proc NatlAcad SciUSA,2005,102:8309-8314.
[25]孔令文.血清C反应蛋白检测与冠心病的关系[J]·中华全科医师杂志,2004.3:384.
[26]Pearson TA,Mensah GA,Alexander RM,et a.l Markers of inflammation and cardiovascular disease:Application to clinical and public health practice:A statement forhealthcare professionals from the Centers forDisease Control and Prevention and the American HeartAssociation[J].Circulation,2003,107:499-511.
[27]Ridker PM,Hennekens CH,Buring JE,et al.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.N Engl J Med,2000,342(12):836-843.
[28]Ayash RS.High-sensitivity C-reactive protein:productclaims and the Food and Drug Administration.Clin Chem,2001,47(9):1743.
[29]Ridker PM.High-sensitivity C-reactive protein:potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.Circulation,2001,103(13):1813-1818.
[30]Kimberly MM,Vesper HW,Caudill SP,et al.Standardization of immunoassays for measurement of high-sensitivity C-reactive protein.Phase Ⅰ:evaluation of secondary reference materials.Clin Chem,2003,49(4):611-616.
[31]CAO H,ROBERTA,HEGELE J,et al.J Hum Genet,2000,45(2):100-101.
[32]EKLUND C T,LEHTIMAKIT M,HURME I,et al.Inter J Immun,2005,32(4):229-232.
[33]SUKH J,RIDER PM,COOK N R,et al.Atherosclerosis,2005,178(1):139-145.
[34]MILLER DT,ZEERY,SUKDANIKJ,et al.AnnHumGenet,2005,69(6):623-638.
[35]CHEN JH,ZHAOJG,HUANG JF,et al.JMolMed,2005,83(1):72-78.
[36]KOVACSA,GREENF,HANSSONL O.Atherosclerosis,2005,178(1):193-198.
[37]赵磊,周新,郑芳,等.中国老年学杂志,2005,25(6):637-639.
[38]徐耕,金国栋,傅国胜,等.中华心血管病杂志,2003,31(4):274-277.
[39]尚小明,赵宝春,戴秀华,等.国外医学内科学分册,2005,32(6):269-273.
[40]VermaS,KuliszewskiMA,Li SH,et al.C-reactive protein attenuates ndothelial progenitor cell survival,diferentiation,and function:further evidence of a mechanistic link between C-reactive protein and cardiovascular disease[J].Circulation,2004;109(17):2058-2067.
[41]BassukS S,RifaiN,RidkerPM.High-sensitivity C-reactive protein:clinical importance[J].Curr Probl Cardiol.2004;29(8):439-493.
[42]BlaschkeF,BruemmerD,YinF,etal.C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells[J].Circulation,2004;110(5):579-587.
[43]DanenbergHD,SzalaiAJ,SwaminathanRV et al.Increased thrombosis after arterial injuryin human C-reactive protein-transgenic mice[J].Circulation,2003;108(5):512-515.
[44]VolanakisJ E.Human C -reactive protein:expression,structure,and function[J].MolImmunol.2001;38(2-3):189-197.
[45]Zee RY,RidkerPM.Polymorphism in the human C-reactive protein(CRP)gene,plasma concentrations of CRP,and the risk of future arterial thrombosis[J].Atherosclerosis,2002;162(1):217-219.
[46]Tohgi H,Takahashi H,Tamura K,et al.Ischemic stroke among inpatents with preceding inflame matory response[J].Thromb Res,2001,104(5):375.
[47]史功,刘玉兰,肖国民.急性脑血管病早期血清C-反应蛋白的测定及意义[J].临床荟萃,1997,12(2):87.
[48]武湘云,李立新,李贵霞.脑血管疾病与血清C-反应蛋白关系的探讨[J].临床荟萃,2004,19(13):751.
[49]高建国,周农,翟金霞.血清C反应蛋白与脑梗死预后的关系[J].临床神经病学杂志,2005,18(1):43-44.
[50]Pepys MB,Hirschfield GM.C-reactive protein:a critical up-date[J].Clin Invest,2003,111:1805-1812.
[51]Nakanishi N,Shiraishi T,Wada M.Association between C-reactive protein and insulin resistance in a Japanese population:the Minoh Study.Intern Med,2005,44(6):542-547.
[52]Howard VJ,Sides EG,Newman GC,et al.Changes in plasma homocysteine in the acute phase after stroke[J].Stroke,2002,33:473-478.
[53]Harry Yu,Nader Rifai.High-sensitivity C-reactive protein and ather sclerosis:from theory to the reply[J].Clinical Biochemistry,2000,33(8):601-601.
[54]张微微,周小英.不同类型脑梗死患者血清C-反应蛋白的检测及临床意义[J].中华检验医学杂志,2004,27:781-783.
[55]RostNS,WolfPA,KaseCS,eta.l Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack:the Framingham study.Stroke,2001,32:2575-2579.
[56]Cao JJ,Thach C,ManolioTA,eta.l C-reactive protein,carotid in tima-media thickness and incidence of ischemic stroke in the elderly:the CardiovascularHealth Study.Circulation,2003,108:166 - 170.
[57]Gussekloo J,SchaapMC,FrolichM,et a.l C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons.Arterioscler Thromb Vasc Bio,l 2000,20:1047-1051.
[58]Di NapoliM,Papa F,Bocola V.C-reactive protein in ischemic stroke:an independentprognostic factor.Stroke,2001,32:917-924.
[59] BALISTRERI C R,VASTO S,LISTI F,et al.Ann N Y Acad Sci,2006,1067(6):276-281.
[60] MORITA A,NAKAYAMA T,SOMA M,et al.Hypertens,2006,19(6):593-600.
[61] ZEE R Y,HEGENERHH,FERNANDEZ C A,et al.Atherosclerosis,2004,176(2):393-396.
[62] HIRSCHFIELD GM,GALLIMORE J,KAHANMC,et al.Natl Acad Sci,2005,102(23):8309-8314.
[63] DOI Y,KIYOHARA Y,KUBO M,et al.Diabetes Care,2005,28(10):2497-2500.
[64] MARIOMD,POMILIOM,VIGNERI S,et al.Diabetes Care,2001,24(9):1674-1678.
[65] Wolford CS,ALDRED SF,LEE PK,et al.Am J Hum Genet2005,77(1):64-74.
[66] SZALAI A J,CRORYMM,COOPER C,et al.Genes and Immunity,2002,3(1):14-19.
[67] RUSSELL A I,CUNNINGHAME G,DEBORAHS,et al.OxfordUni-versity Press,2004,13(1):137-147.
[68] THALMAIERD,DAMBACHER J,SEIDERER J,et al.AlimentPhar-macol Ther,2006,24(7):115-117.
[69] WILLOT S,VERMEIRE S,OHRESSER M,et al.Pharmacogenet Genomics,2006,16(1):37-42.
[70] EBERSOLE J L,MACHEN R L,STEFFENM J,et al.J Clinical &Experimental Immunology,1997,107(2):347-352.]
[71] MIRANDALA,FISCHER RG,SZTAJNBOKFR,et al.J Clin Periodontal,2003,30(11):969-974.
[72] D'AIUTO F,READY D,TONETTI M S,et al.J Periodont Res,2004,39(4):236-241.
[73]SLADE G D,OFFENBACHER S,BECK J D,J Dent Res,2000,79(1):49-57.
[74]MARSIK C,SUNDER P R,JILMA B,et al.Clin Chem,2006,52(10):1952-1957.
[75]Tataru M C,Heinrich J,Junker R,et al.C-reactive protein and the severity of otherosclerosis in myocardial infarction patiens with stable angina pectoris[J].Eur Heart J,2002,21(12 ):1000.
[76]徐光燕,邓志宽.阿司匹林对脑梗死患者血清C反应蛋白含量的影响及意义[J].中国临床康复,2003,7(28):3814-3815.
[77]Chen YG,Xu F,Zhang Y,et al.Effect of aspirin plus clopi-dogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.Chin Med J(Engl)2006,119:32-36.
[78]Solheim S,AmesenH,EikvarL,et a.l Influence of aspirin on inflammatory markers in patients after acutemyocardial infarction.Am JCardioj 2003,92:843-845.
[79]Ikonomids I,AndreottiF,Economon E,eta.l Increased proinflam-matory cytokines in patientswith chronic stable angina and their reduction by aspirin.Circulation,1999,100:793-798.
[80]A zar RR,Klayme S,GermanosM,et al Effects of aspirin(325mg/day) on serum high-sensitivity C-reactive protein,cytokines,and adhesionmolecules in healthy volunteers.Am JCardioj 2003,92:236-239.
[81]Ridker PM;Cushman M;Stampfer MJ et al.Inflammation,Aspirin,and the Risk of C ardiovascularD iseasein Apparently Healthy Men N.Engl.J.Med.1997;336:973-979.
[82]KennonS,PriceCP,MillsGP et al.The efect of aspirin on C -reactivep rotein as a marker of risk inunstable angina.J Am Coll Cardiol2001;37:1226-70
[83]LangloisM,DuprezD,DelangheJ et al.Serum VitamionC concentrationis low inperiph eralart erial disease and is associated within flammation and ather osclerosis.Circulation2001:1863-8.
[84]曾红,孙长凯,赵杰,等.他汀类药物对脑梗死患者血清C反应蛋白的影响
及其临床意义[J].中华神经科杂志,2005,38(5):329-330.
[85]Luo Y,Jiang D,Wen D,et al.Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin.Heart Vessels,2004,19:257-262.
[86]Ansell BJ,Watson KE,Weiss RE,et al.hsCRP and HDL effects of statins trial (CHEST):rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels.A clinical investigation.Heart Dis,2003,5:2-7.
[87]Hoshida S,Nishino M,Takeda T,et al.A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins.Atheroscle-rosis,2004,173:285-290.
[88]YudkinJ S,StehhouwerC DA,EmeisJ J etal.C-eractive protein in healthy subject:association with obesity,insulin resistance,and endothelial dysfunction.Arterioscler Thromb VaseBiol 1999;19:972-8.
[89]Hans C.Ablij,Arend E.Meinders C-reactive protein:history and revival.European J.of intenral Med2002;13:4 12-22.
[90]Chan DC;Wats GF;Barret PH et al.Efect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuas withvisceral obesity.Clin Chem.2002Jun;48(6):877-883.
[91]董玉秋.青霉素对急性脑梗死患者血清CRP的影响及疗效观察[J].山东医药2005,45(22):31.
[92]DiNapoliM,Papa F.Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration ofC-reactive protein in patientswith first-ever ischemic stroke.Stroke,2003,34:2922-2929.
[93]Jenkins NP,Keevil BG,Hutchinson Ⅳ,et al.Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.Am J Med,2002,112:269-274.
[94]Pepys MB,Hirschfield GM,Tennent GA,et al.Targeting C-reactive protein for the treatment of cardiovascular disease.Nature,2006,440:1217-1221.